Background
As confirmed by several randomized clinical trials (RCTs), consensus
documents, and meta-analyses, allergen immunotherapy (AIT) has led to
crucial changes in clinical outcomes compared to standard treatments in
selected patients, as it is the only therapeutic approach able to modify
the underlying course of the disease and recover from the disease
[1-4].
Despite the presence of robust evidence, very sparse data [5] are
available on the efficacy of AIT on selected patients inreal-life , a research method that takes into account realfactors of daily clinical life, and aims to evaluate the true
effectiveness of innovative therapies.
With the aim to fill this gap, we performed a pilot, monocenter,
retrospective cohort study to evaluate real-life data on efficacy
and perceived satisfaction of 3-year sublingual immunotherapy (SLIT),
measured by a validated questionnaire, in a population of mono- or
poly-sensitized patients with allergic rhinitis and/or asthma.